FAQs

PADCEV works differently from the chemotherapy or immunotherapy you may have had before because PADCEV is an antibody-drug conjugate (ADC). PADCEV works by delivering medicine directly to certain cancer cells, but can also harm normal cells and cause side effects. See more on How PADCEV Works.

PADCEV may cause serious side effects, including:

• Skin reactions. Skin reactions including severe skin reactions have happened in people treated with PADCEV and may be more common when PADCEV is given with pembrolizumab. In some cases, these severe skin reactions have caused death. Most severe skin reactions occurred during the first cycle of treatment but may happen later. Your healthcare provider will monitor you, may stop your treatment with PADCEV completely or for a period of time (temporarily), may change your dose, and may prescribe medicines if you get skin reactions. Tell your healthcare provider right away if you develop any of these signs of a new or worsening skin reaction:
• Target lesions (skin reactions that look like rings)
• Rash or itching that continues to get worse
• Blistering or peeling of the skin
• Painful sores or ulcers in mouth or nose, throat, or genital area
• Fever or flu-like symptoms
• Swollen lymph nodes
• High blood sugar (hyperglycemia). An increase in blood sugar is common during treatment with PADCEV. Severe high blood sugar, a serious condition called diabetic ketoacidosis (DKA), and death have happened in people with and without diabetes treated with PADCEV. Tell your healthcare provider right away if you have any symptoms of high blood sugar, including: frequent urination, increased thirst, blurred vision, confusion, it becomes harder to control your blood sugar, drowsiness, loss of appetite, fruity smell on your breath, nausea, vomiting, or stomach pain.
• Lung problems. PADCEV may cause severe or life-threatening inflammation of the lungs that can lead to death. These severe problems may happen more often when PADCEV is given in combination with pembrolizumab. Tell your healthcare provider right away if you get new or worsening symptoms, including trouble breathing, shortness of breath, or cough.
• Nerve problems. Nerve problems, called peripheral neuropathy, are common during treatment with PADCEV and can sometimes be severe. Nerve problems may happen more often when PADCEV is given in combination with pembrolizumab. Tell your healthcare provider right away if you get new or worsening numbness or tingling in your hands or feet or muscle weakness.
• Eye problems. Certain eye problems are common during treatment with PADCEV. Tell your healthcare provider right away if you have dry eyes, increased tearing, blurred vision, or any vision changes. You may use artificial tear substitutes to help prevent or treat dry eyes.
• Leakage of PADCEV out of your vein into the tissues around your infusion site (extravasation). If PADCEV leaks from the injection site or the vein into the nearby skin and tissues, it could cause an infusion site reaction. These reactions can happen right after you receive an infusion, but sometimes may happen days after your infusion. Tell your healthcare provider or get medical help right away if you notice any redness, swelling, itching, blisters, peeling skin or discomfort at the infusion site.

Learn more about the most common side effects that may happen during treatment. Be sure to report any symptoms when you first experience them. Tell your healthcare team if any of the symptoms get worse. If your healthcare provider prescribes PADCEV in combination with pembrolizumab for you, also read the Medication Guide that comes with pembrolizumab for important information about pembrolizumab.

Side effects may occur with PADCEV. You and your caregiver(s) should always talk to your doctor or nurse right away about any side effects you experience, or if these get worse. Learn more about Possible Side Effects with PADCEV.

You may report side effects to the FDA at 1‑800‑FDA‑1088 or www.fda.gov/medwatch.

You will receive PADCEV by intravenous (IV) infusion. Each infusion will be given at either your healthcare professional’s office or an infusion center. PADCEV is given over periods of time called “cycles.”

Each PADCEV with pembrolizumab cycle is 21 days. PADCEV is given by IV infusion for 30 minutes on days 1 and 8. Pembrolizumab is then given by IV infusion about 30 minutes after PADCEV on day 1.

When given alone, each PADCEV treatment cycle is 28 days. Within each cycle, you will receive PADCEV on days 1, 8, and 15. Each infusion should take 30 minutes.

Talk with your healthcare team for the best way to schedule your appointments. Your healthcare professional will determine how many treatment cycles you need. Learn more about How PADCEV Is Given.

Yes, PADCEV Support Solutions^SM offers access and reimbursement support to help patients like you, who have been prescribed PADCEV, access their medication. Call PADCEV Support Solutions at 1-888-402-0627 Monday-Friday, 8:30 AM to 8:00 PM ET if you have any questions or need assistance.

Yes, resources are available for you to download on our website, and can be found on our Downloads page. These resources can help you learn more about PADCEV and start conversations with your healthcare team.